208 related articles for article (PubMed ID: 25096997)
1. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
2. Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 study.
Castellano D; Bajetta E; Panneerselvam A; Saletan S; Kocha W; O'Dorisio T; Anthony LB; Hobday T;
Oncologist; 2013; 18(1):46-53. PubMed ID: 23263288
[TBL] [Abstract][Full Text] [Related]
3. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World.
Strosberg J; Joish VN; Giacalone S; Perez-Olle R; Fish-Steagall A; Kapoor K; Dharba S; Lapuerta P; Benson AB
Oncologist; 2019 Nov; 24(11):1446-1452. PubMed ID: 31189618
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
Anthony LB; Kulke MH; Caplin ME; Bergsland E; Öberg K; Pavel M; Hörsch D; Warner RRP; O'Dorisio TM; Dillon JS; Lapuerta P; Kassler-Taub K; Jiang W
Oncologist; 2019 Aug; 24(8):e662-e670. PubMed ID: 30651397
[TBL] [Abstract][Full Text] [Related]
6. Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
Clarke CN; Cockrum P; Beveridge TJR; Jerry M; McMorrow D; Tran AT; Phan AT
J Health Econ Outcomes Res; 2023; 10(2):121-131. PubMed ID: 38093906
[No Abstract] [Full Text] [Related]
7. Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients With Neuroendocrine Tumors and Carcinoid Syndrome.
Liu E; Hoffman KD; Murfin G; Eccard H
Pancreas; 2023 Jan; 52(1):e70-e74. PubMed ID: 37378902
[TBL] [Abstract][Full Text] [Related]
8. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome.
Koumarianou A; Daskalakis K; Tsoli M; Kaltsas G; Pavel M
J Neuroendocrinol; 2022 Jul; 34(7):e13174. PubMed ID: 35794780
[TBL] [Abstract][Full Text] [Related]
11. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellström L; Liedman H; Svedberg A; Tiberg F
Trials; 2024 Jan; 25(1):58. PubMed ID: 38229199
[TBL] [Abstract][Full Text] [Related]
12. Management of Diarrhea in Patients With Carcinoid Syndrome.
Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
[TBL] [Abstract][Full Text] [Related]
13. Surgery Improves Patient-Reported Outcomes in Patients with Intestinal and Pancreatic NETs: A Prospective Analysis.
Rosowicz A; Bangla VG; Johnson JW; Olson L; Chen J; Divino CM
Ann Surg Oncol; 2023 Oct; 30(11):6777-6785. PubMed ID: 37349613
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid syndrome and somatostatin analogues.
Varas Lorenzo M
Rev Esp Enferm Dig; 2023 Dec; 115(12):726-727. PubMed ID: 36896924
[TBL] [Abstract][Full Text] [Related]
15. Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study.
von Arx C; Rea G; Napolitano M; Ottaiano A; Tatangelo F; Izzo F; Petrillo A; Clemente O; Di Sarno A; Botti G; Scala S; Tafuto S
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32859050
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Recurrence of Typical Pulmonary Carcinoid Accompanied by Carcinoid Syndrome, Successfully Treated with Octreotide LAR.
Yanagisawa A; Hirano S; Shimizu S; Hiroishi T; Shikano K; Hayama N; Fujita T; Amano H; Nakamura M; Nakamura S; Tabeta H
Case Rep Oncol Med; 2017; 2017():1564819. PubMed ID: 29445555
[TBL] [Abstract][Full Text] [Related]
17. Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study.
Kulke MH; Kennecke HF; Murali K; Joish VN
Cancer Manag Res; 2021; 13():7439-7446. PubMed ID: 34611437
[TBL] [Abstract][Full Text] [Related]
18. First Case of Regression of Carcinoid Heart Disease on Serial Transthoracic Echocardiograms following Octreotide Monotherapy in a Patient with Metastatic Pancreatic Neuroendocrine Tumor.
Nath E; Sawyer MB; Choy J
Case Rep Oncol; 2020; 13(3):1454-1462. PubMed ID: 33442370
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Octreotide and Vasopressors as First-Line Treatment for Intraoperative Carcinoid Crisis.
McCully BH; Kozuma K; Pommier S; Pommier RF
Ann Surg Oncol; 2024 May; 31(5):2996-3002. PubMed ID: 38227166
[TBL] [Abstract][Full Text] [Related]
20. Refractory carcinoid syndrome: a review of treatment options.
Riechelmann RP; Pereira AA; Rego JF; Costa FP
Ther Adv Med Oncol; 2017 Feb; 9(2):127-137. PubMed ID: 28203303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
